OnCore Biopharma Agrees to Acquire Enantigen Therapeutics
01 oct. 2014 02h00 HE
|
OnCore Biopharma, Inc.
DOYLESTOWN, Pa., Oct. 1, 2014 (GLOBE NEWSWIRE) -- OnCore Biopharma, Inc. ("OnCore" or the "Company"), a biotechnology company focused on the research, development and commercialization of oral...
OnCore Biopharma Closes Series R Financing
05 sept. 2014 07h00 HE
|
OnCore Biopharma, Inc.
Funds to Expand OnCore's Portfolio of Oral Therapeutics for the Treatment of Chronic HBV
OnCore to Advance HBV Compounds Into Phase 1 Clinical Development During 2015
Former Pharmasset Team...